|
| Press Releases |
|
 |
|
| Thursday, October 30, 2025 |
|
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiary, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection ("MG-K10" or the "Product"). more info >> |
|
| Monday, October 27, 2025 |
|
|
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R) |
| more info >> |
|
| Sunday, September 28, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the "Trial") of ruxolitinib cream (the "Product") in patients with mild to moderate atopic dermatitis (AD) in China. more info >> |
|
| Tuesday, September 23, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively. more info >> |
|
| Tuesday, August 19, 2025 |
|
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers |
| On 18 August, China Medical System Holdings Limited ("CMS" or the "Company") announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. more info >> |
|
| Tuesday, July 29, 2025 |
|
|
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) ("ZUNVEYL" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 22, 2025 |
|
|
CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets |
| On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited ("CMS" or the "Group") on the Main Board of the Singapore Exchange ("SGX"), SGX and CMS co-hosted the "Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner". more info >> |
|
| Monday, April 1, 2024 |
|
|
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia |
| more info >> |
|
| Monday, March 7, 2011 |
|
|
China Medical System Accredited by 'China's Top 100 Potential Enterprises' by Forbes China for Two Consecutive Years |
| Compiled by Forbes China, the "China's Top 100 Potential Enterprises" list focuses on the SMEs in China, and is the first ranking of its kind to cover the SMEs across all industries. more info >> |
|
| Friday, January 28, 2011 |
|
|
CMS Expects to Launch CMS024 for the Treatment of Primary Liver Carcinoma Three Years Ahead of Plan in 2013 |
| China Medical Systems, its subsidiary and Kangzhe Pharmaceutical Research and Development (Shenzhen) Limited held a successful roundtable meeting with the State Food and Drug Administration ("SFDA") of China. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Oct 30, 2025 23:14 JST
|
|
|
NEC and e& Sign MoU to Drive Joint Sustainability Initiatives
Oct 30, 2025 22:46 JST
|
|
|
MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market
Oct 30, 2025 22:19 JST
|
|
|
Decent Cybersecurity Highlights Slovakia's Tech Leadership at the EU-NZ Business Summit 
Oct 30, 2025 21:00 HKT/SGT
|
|
|
Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America
Oct 30, 2025 21:40 JST
|
|
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 20:00 HKT/SGT
|
|
|
Esperanza Unveils New Milestone in Tokenized Economy
Oct 30, 2025 19:09 HKT/SGT
|
|
|
MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa
Oct 30, 2025 17:58 JST
|
|
|
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Oct 30, 2025 16:48 HKT/SGT
|
|
|
DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025
Oct 30, 2025 17:29 JST
|
|
|
Northeast Asia Video Summit Spotlights Global Content Strategies, Streaming Innovation, and the Future of Media Monetization
Oct 30, 2025 15:00 HKT/SGT
|
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 14:43 JST
|
|
|
Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025
Oct 30, 2025 14:33 JST
|
|
|
Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 30, 2025 14:26 JST
|
|
|
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
Oct 30, 2025 14:18 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
